Nikolaus Jilg

3.6k total citations
27 papers, 882 citations indexed

About

Nikolaus Jilg is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Nikolaus Jilg has authored 27 papers receiving a total of 882 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hepatology, 9 papers in Epidemiology and 7 papers in Infectious Diseases. Recurrent topics in Nikolaus Jilg's work include Hepatitis C virus research (11 papers), Liver Disease Diagnosis and Treatment (5 papers) and interferon and immune responses (4 papers). Nikolaus Jilg is often cited by papers focused on Hepatitis C virus research (11 papers), Liver Disease Diagnosis and Treatment (5 papers) and interferon and immune responses (4 papers). Nikolaus Jilg collaborates with scholars based in United States, China and France. Nikolaus Jilg's co-authors include Lee F. Peng, Wenyu Lin, Raymond T. Chung, Kaku Goto, Dahlene N. Fusco, Leiliang Zhang, Korbinian Brand, Sharon Page, Hong Zhao and Martina Quirling and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Gastroenterology.

In The Last Decade

Nikolaus Jilg

25 papers receiving 867 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nikolaus Jilg United States 16 394 353 290 189 151 27 882
Olivier Diaz France 18 405 1.0× 596 1.7× 200 0.7× 335 1.8× 75 0.5× 30 1.2k
György Ábel United States 13 865 2.2× 673 1.9× 237 0.8× 221 1.2× 70 0.5× 31 1.5k
Kanji Tsuchimoto Japan 18 193 0.5× 260 0.7× 157 0.5× 263 1.4× 100 0.7× 82 906
Juandy Jo Indonesia 12 530 1.3× 616 1.7× 640 2.2× 252 1.3× 72 0.5× 33 1.3k
Guangyun Tan China 17 272 0.7× 356 1.0× 385 1.3× 331 1.8× 66 0.4× 30 962
Xiaojin Liu China 11 81 0.2× 105 0.3× 158 0.5× 199 1.1× 67 0.4× 26 585
Kaku Goto Japan 21 752 1.9× 596 1.7× 367 1.3× 391 2.1× 227 1.5× 41 1.4k
Qing Guo China 15 351 0.9× 437 1.2× 124 0.4× 78 0.4× 44 0.3× 41 692

Countries citing papers authored by Nikolaus Jilg

Since Specialization
Citations

This map shows the geographic impact of Nikolaus Jilg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nikolaus Jilg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nikolaus Jilg more than expected).

Fields of papers citing papers by Nikolaus Jilg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nikolaus Jilg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nikolaus Jilg. The network helps show where Nikolaus Jilg may publish in the future.

Co-authorship network of co-authors of Nikolaus Jilg

This figure shows the co-authorship network connecting the top 25 collaborators of Nikolaus Jilg. A scholar is included among the top collaborators of Nikolaus Jilg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nikolaus Jilg. Nikolaus Jilg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wohl, David A., Stacey J. Adam, Kevin W. Gibbs, et al.. (2024). Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative. Journal of Clinical and Translational Science. 8(1). e156–e156. 1 indexed citations
2.
Jilg, Nikolaus, Mark J Giganti, Kara W Chew, et al.. (2024). SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19. Clinical Infectious Diseases. 79(4). 920–927.
3.
Kim, Myung‐Ho, Nikolaus Jilg, Jenna Gustafson, et al.. (2023). Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial. Frontiers in Medicine. 10. 1095828–1095828. 1 indexed citations
4.
Mohareb, Amir M., Jacob M. Rosenberg, Roby P. Bhattacharyya, et al.. (2021). Preventing Infectious Complications of Immunomodulation in COVID-19 in Foreign-Born Patients. Journal of Immigrant and Minority Health. 23(6). 1343–1347. 5 indexed citations
5.
Vaidya, Anand, et al.. (2021). A Treacherous Course. New England Journal of Medicine. 384(5). e10–e10.
6.
Geisler, Benjamin P., et al.. (2019). Model to evaluate the impact of hospital-based interventions targeting false-positive blood cultures on economic and clinical outcomes. Journal of Hospital Infection. 102(4). 438–444. 16 indexed citations
7.
Kumthip, Kattareeya, Jian Hong, Chuanlong Zhu, et al.. (2016). HCV induces transforming growth factor β1 through activation of endoplasmic reticulum stress and the unfolded protein response. Scientific Reports. 6(1). 22487–22487. 58 indexed citations
8.
Lin, Wenyu, Chuanlong Zhu, Jian Hong, et al.. (2014). The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing. Journal of Hepatology. 62(5). 1024–1032. 21 indexed citations
9.
Fofana, Isabel, Nikolaus Jilg, Raymond Chung, & Thomas F. Baumert. (2014). Entry inhibitors and future treatment of hepatitis C. Antiviral Research. 104. 136–142. 17 indexed citations
10.
Jilg, Nikolaus, Wenyu Lin, Jian Hong, et al.. (2013). Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology. 59(4). 1250–1261. 89 indexed citations
11.
Chung, Raymond T., Wenyu Lin, Chuanlong Zhu, et al.. (2013). Health care quality and cost effectiveness. Hepatology. 58(S1). 328A–331A. 3 indexed citations
12.
Fusco, Dahlene N., Cynthia Brisac, Sinu P. John, et al.. (2013). A Genetic Screen Identifies Interferon-α Effector Genes Required to Suppress Hepatitis C Virus Replication. Gastroenterology. 144(7). 1438–1449.e9. 30 indexed citations
13.
Kumthip, Kattareeya, Nikolaus Jilg, Lei Zhao, et al.. (2012). Hepatitis C Virus NS5A Disrupts STAT1 Phosphorylation and Suppresses Type I Interferon Signaling. Journal of Virology. 86(16). 8581–8591. 68 indexed citations
14.
Shao, Run–Xuan, Leiliang Zhang, Zhi Hong, et al.. (2012). SOCS1 abrogates IFN’s antiviral effect on hepatitis C virus replication. Antiviral Research. 97(2). 101–107. 20 indexed citations
15.
Zhao, Hong, Wenyu Lin, Kattareeya Kumthip, et al.. (2011). A functional genomic screen reveals novel host genes that mediate interferon-alpha’s effects against hepatitis C virus. Journal of Hepatology. 56(2). 326–333. 50 indexed citations
16.
Jang, Jae Young, Run–Xuan Shao, Wenyu Lin, et al.. (2010). HIV infection increases HCV-induced hepatocyte apoptosis. Journal of Hepatology. 54(4). 612–620. 44 indexed citations
17.
Zhang, Leiliang, Nikolaus Jilg, Run–Xuan Shao, et al.. (2010). IL28B inhibits hepatitis C virus replication through the JAK–STAT pathway. Journal of Hepatology. 55(2). 289–298. 112 indexed citations
18.
Quirling, Martina, Sharon Page, Nikolaus Jilg, et al.. (2004). Detection of IKKβ-IKKγ Subcomplexes in Monocytic Cells and Characterization of Associated Signaling. Journal of Biological Chemistry. 279(36). 37452–37460. 9 indexed citations
19.
Degitz, Klaus, et al.. (2003). Involvement of NF-κB signalling in skin physiology and disease. Cellular Signalling. 15(1). 1–7. 148 indexed citations
20.
Fischer, Claudia, Sharon Page, Nikolaus Jilg, et al.. (2002). Chlamydia pneumoniae activates IKK/IκB-mediated signaling, which is inhibited by 4-HNE and following primary exposure. Atherosclerosis. 165(1). 79–88. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olivier Diaz Breakdown of academic impact, for papers by György Ábel Breakdown of academic impact, for papers by Kanji Tsuchimoto Breakdown of academic impact, for papers by Juandy Jo Breakdown of academic impact, for papers by Guangyun Tan Breakdown of academic impact, for papers by Xiaojin Liu Breakdown of academic impact, for papers by Kaku Goto Breakdown of academic impact, for papers by Qing Guo
Rankless by CCL
2026